SCHEMBL23846500

SCHEMBL23846500

COc1ccc(N)cc1S(=O)(=O)Nc1ccc(F)cc1

nearest known ligand 0.73

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.73
SMN1; SMN2 Q16637 5/20 0.69
HTT P42858 1/20 0.69
ALDH1A1 P00352 2/20 0.63
MEN1 O00255 2/20 0.63
KMT2A Q03164 2/20 0.63
CYP1A2 P05177 1/20 0.63
GLA P06280 1/20 0.63
CYP3A4 P08684 1/20 0.63
CYP2D6 P10635 1/20 0.63
CYP2C9 P11712 1/20 0.63
PKM P14618 1/20 0.63
CYP2C19 P33261 1/20 0.63
RECQL P46063 1/20 0.63
HPGD P15428 1/20 0.59
MAPT P10636 1/20 0.56
GAA P10253 1/20 0.56
HSD17B10 Q99714 1/20 0.56
ALPL P05186 3/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23846503 0.87 SMN1; SMN2 (0.71) LMNASMN1; SMN2HTTALDH1A1MEN1
SCHEMBL17980891 0.86 MAPT (0.60) LMNASMN1; SMN2HTTALDH1A1MEN1
SCHEMBL25754817 0.86 NPSR1 (0.62) LMNASMN1; SMN2HTTMEN1KMT2A
SCHEMBL23847019 0.86 MEN1 (0.61) LMNASMN1; SMN2HTTALDH1A1MEN1
SCHEMBL23833737 0.85 MEN1 (0.63) LMNASMN1; SMN2HTTMEN1KMT2A
SCHEMBL23847027 0.85 MEN1 (0.59) LMNASMN1; SMN2HTTALDH1A1MEN1
SCHEMBL7536903 0.84 LMNA (0.75) LMNASMN1; SMN2HTTALDH1A1MEN1
SCHEMBL23846529 0.84 ALPL (0.60) LMNASMN1; SMN2HTTMEN1KMT2A
SCHEMBL7571589 0.83 LMNA (0.73) LMNASMN1; SMN2HTTALDH1A1MEN1
SCHEMBL21761109 0.83 LMNA (0.73) LMNASMN1; SMN2HTTALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230174523-A1 BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2023-06-08 US disclosed
US-20230174523-A1 BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2023-06-08 US disclosed
WO-2021188880-A1 BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2021-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174523-A1 BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF TRAP1, PINK1, TP53BP1 LMNA 3435/4885SMN1; SMN2 405/4885HTT 69/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.